• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Mass. Sen. hopeful Elizabeth Warren on the device tax, the FDA and a climate for innovation

Mass. Sen. hopeful Elizabeth Warren on the device tax, the FDA and a climate for innovation

April 17, 2012 By MassDevice

Elizabeth Warren

A climate for innovation

by Elizabeth Warren

When it comes to turning good ideas into innovative businesses, Massachusetts has always set the standard. From Alexander Graham Bell’s telephone in 1876 to the microwave in 1945 to iWalk’s bionic ankle just last year, we’ve proven that we’re the most innovative place in the world.

Innovation is a vital part of who we are.  Here in the Commonwealth, the medical device and diagnostics industry employs around 24,000 people and is responsible for 13 percent of all state exports. I am proud that Massachusetts companies are creating the new treatments, diagnostics, and cures that lead to better and longer lives for millions of patients.  Innovation is important, and we should do everything that we can to create a stronger climate for it.

Innovation starts with a creative spark—but that spark turns into a great invention only if the right conditions are in place. Steady financing and a smart, highly skilled team are critical.  The government also plays a critical role in speeding – or slowing – the pace of innovation. Three changes in government policy are essential: a more efficient regulatory system at the FDA, repeal of the medical device tax, and an increased national commitment to research and education.

There is no greater problem facing the medical technology industry than the decline in FDA performance in recent years. In February, the Government Accountability Office, an independent, non-partisan agency in Washington, released a report showing that the time the FDA takes to reach a final decision in 510(k) and PMA submissions has increased substantially. From 2005 (when the first performance goals were in place) to 2010, the average time to final decision for a 510(k) increased from 100 days to 161 days—a 61% increase. The decision time for original PMA products increased from an already lengthy 462 days in 2003 to 627 days in 2008 (the last year for which complete data is available)—a 35% increase.  This is the wrong trend line.  FDA delays drive up costs for innovators hoping to launch new products, deterring the early investment that is essential for new product development, and depriving American patients access to improved therapies.

The solution to the problem isn’t to cut funding or to attack regulators.  That won’t do anything to make the system more efficient.  What we really need is smarter regulation—and some fresh ideas for how to get there.

When I was setting up the Consumer Financial Protection Bureau, my goal was to build a 21st century agency that would be effective and efficient. We recruited smart, talented people who were committed to the mission of making consumer credit markets work for regular people. We focused on creating simple, streamlined, and easy to understand regulations, like combining multiple mortgage disclosure forms into one and cutting the fine print that can hide tricks and traps in credit cards. We made it easier for customers to understand credit agreements while also pushing to reduce regulatory costs and level the playing field for smaller institutions.

We need a similar approach at the FDA. The FDA works hard to keep patients safe, and let’s be clear: its work saves lives. But the FDA needs to be able to put life-saving devices on the market quickly. Delays and regulatory uncertainty don’t just hurt companies – they hurt the patients and families who rely on those devices. The FDA can also provide better guidance documents that are simple, clear, and up-to-date.  This is particularly important for the small businesses that don’t have an army of lawyers to help them navigate complex processes and requirements.

The recently negotiated user fee agreement between FDA and industry is an important step forward to address some of these issues. As part of the user fee agreement, the industry came to the negotiating table and doubled the amount they were willing to contribute. Now Congress needs to do its part by moving quickly to reauthorize the Medical Device User Fee Act and fully fund the FDA’s Center for Devices and Radiological Health. User fees are intended for product review – not to fund the FDA’s other functions. Congress must ensure the FDA has the appropriated funds necessary to be an effective and efficient agency that can attract highly qualified professionals.

Warren

Smarter regulation is key, but it isn’t enough: innovation also depends on a fair tax system. When Congress taxes the sale of a specific product through an excise tax, as the Affordable Care Act does with medical devices, it too often disproportionately impacts the small companies with the narrowest financial margins and the broadest innovative potential. It also pushes companies of all sizes to cut back on research and development for life-saving products. With an appropriate offset, we can repeal the medical device tax without cutting health care coverage for millions of people or forcing Americans to fight the whole health care battle all over again.

Finally, we can nurture continued innovation with a national commitment to research, development, and education, including university-based research and education. R&D creates the pipeline of ideas – the innovations and experiments that fuel breakthrough technologies, lead to lifesaving inventions, and spawn successful businesses. Massachusetts companies alone spent $2.6 billion on R&D in 2010. Nationally, American device companies invest a whopping 13 percent of their sales in research and development.

Unfortunately, our national commitment to R&D has faded. Instead of making the R&D tax credit permanent, Congress has let it lapse. Congress has also slashed federal support for research, as a percentage of GDP, by more than half since the 1960s. Basic science research by NASA and the NIH has been critical to the breakthroughs in medicine, in computing, and in materials science that have helped medical technology companies innovate. Without robust government funding of research and strong pipeline of scientists and engineers, America cannot foster an innovative future.

Investments in a better FDA, in fairer tax laws, and in research and development are critical to a strong medical technology industry and a strong economy. As a Commonwealth and as a country, we must strive to be the most innovative place in the world – but we will only achieve that goal if we dedicate ourselves to creating a climate for innovation.  It is up to us here in Massachusetts to lead the way. 

Filed Under: News Well Tagged With: 510(k) reforms, U.S. Senate

In case you missed it

  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

RSS From Medical Design & Outsourcing

  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS